Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-A03469-44 | Other Identifier | 2017-A03469-44 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recent evidence suggests a decline in fertility of persons living with HIV (PLWH) (delayed pregnancies, sponteanous abortions, especially when patients receive an antiretroviral therapy, early menopause, amenorrhea and anovulatory cycles) with a possible decrease in ovarian reserve. However, indications of fertility preservation by freezing oocytes are nevertheless not clearly identified.
The objective of this study is to evaluate the ovarian reserve before and after the implementation of antiretroviral treatment in PLWH for whom the diagnosis of HIV has just been made.
This is a monocentric prospective cohort study with minimal risk and constraints. Ovarian reserve is compared between two groups: 30 PLWH, at time of diagnosis and 6, 12 and 18 months after initiation of an antiretroviral therapy, and 30 HIV negative women attending medically assisted procreation consultation for male infertility, age, BMI and smoking habits matched.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| case | Experimental | PLWH |
|
| control | Other | HIV negative women, going to medically assisted procreation consultation for male infertility |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AMH test | Diagnostic Test | Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve |
|
| Measure | Description | Time Frame |
|---|---|---|
| change from inclusion visit AMH level at 18 months | blood test to evaluate ovarian reserve thanks to AMH | M0 (inclusion visit) and M18 (after 18 months) |
| Measure | Description | Time Frame |
|---|---|---|
| antral follicle count | pelvic ultrasound to evaluate ovarian reserve thanks to antral follicle count | Month 0 (inclusion visit), Month 6 (after 6 months), Month12 (after one year), Month18 (after 18 months) |
| estradiol, lutenizing hormone and follicle-stimulating hormone test |
Not provided
Inclusion Criteria:
Case group only :
Control group only :
Exclusion Criteria:
Control group only :
- suspected HIV infection
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Patrick LACARIN | Contact | 0473751195 | placarin@chu-clermontferrand.fr |
| Name | Affiliation | Role |
|---|---|---|
| Florence BRUGNON | University Hospital, Clermont-Ferrand | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu Clermont-Ferrand | Clermont-Ferrand | 63003 | France |
Not provided
| ID | Term |
|---|---|
| D007246 | Infertility |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
No masking
Not provided
| pelvic ultrasound | Diagnostic Test | Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve |
|
blood test |
| Month 0 (inclusion visit), Month 6 (after 6 months), Month 12 (after one year), Month18 (after 18 months) |